Literature DB >> 29551002

Human pegivirus (HPgV) infection in Ghanaians co-infected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV).

Kombo F N'Guessan1, Ceejay Boyce1, Awewura Kwara2, Timothy N A Archampong3,4, Margaret Lartey3,4, Kwamena W Sagoe5, Ernest Kenu4,6, Adjoa Obo-Akwa3, Jason T Blackard7.   

Abstract

Human pegivirus (HPgV) is a positive single-stranded RNA virus in the Flaviviridae family. Phylogenetic analysis reveals the presence of multiple HPgV genotypes with distinct geographic locations. HPgV is of interest because of its potential beneficial impact on HIV disease progression. Despite this, the effects of HPgV in the context of other viral infections, such as hepatitis B virus (HBV), are poorly understood, and data from resource-limited settings are scarce. Therefore, we conducted a cross-sectional analysis of HPgV in HIV/HBV co-infected patients in Ghana. Sera from 100 HIV/HBV co-infected individuals were evaluated for HPgV RNA, and the genotype determined by sequencing the 5' untranslated region. HPgV RNA was detected in 27 samples (27%). Of these, 26 were genotyped successfully with 23 belonging to HPgV genotype 1 and 3 belonging to HPgV genotype 2. The presence of HPgV RNA had no statistically significant impact on CD4 cell count or HBV DNA titers in the HIV/HBV co-infected patients. However, there was a trend towards decreased HBV DNA levels in HPgV RNA-positive patients with CD4 cell count < 200 (p = 0.0626). HPgV co-infection is common in Ghana. The effect of HPgV on HIV or HBV disease among HIV/HBV co-infected patients was minimal. However, decreased HBV DNA levels in HPgV RNA-positive patients with low CD4 cell counts highlight the need for prospective studies of HPgV in HIV and hepatitis co-infected patients, especially in those with advanced HIV disease, to study further the effects of HPgV on liver disease.

Entities:  

Keywords:  Africa; GB virus C (GBV-C); Ghana; HIV; Hepatitis B virus (HBV); Pegivirus (HPgV)

Mesh:

Year:  2018        PMID: 29551002      PMCID: PMC5953819          DOI: 10.1007/s11262-018-1555-2

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  39 in total

1.  The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men.

Authors:  N Bodsworth; B Donovan; B N Nightingale
Journal:  J Infect Dis       Date:  1989-10       Impact factor: 5.226

2.  Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection.

Authors:  R J Gilson; A E Hawkins; M R Beecham; E Ross; J Waite; M Briggs; T McNally; G E Kelly; R S Tedder; I V Weller
Journal:  AIDS       Date:  1997-04       Impact factor: 4.177

3.  GB virus C genotype determination in GB virus-C/HIV co-infected individuals.

Authors:  A Scott Muerhoff; Hans L Tillmann; Michael P Manns; George J Dawson; Suresh M Desai
Journal:  J Med Virol       Date:  2003-05       Impact factor: 2.327

Review 4.  GB virus C: insights into co-infection.

Authors:  Mark D Berzsenyi; D Scott Bowden; Stuart K Roberts
Journal:  J Clin Virol       Date:  2005-08       Impact factor: 3.168

5.  Prevalence and distribution of the GBV-C/HGV among HIV-1-infected patients under anti-retroviral therapy.

Authors:  Rosana Alcalde; Anna Nishiya; Jorge Casseb; Lilian Inocêncio; Luiz A M Fonseca; Alberto J S Duarte
Journal:  Virus Res       Date:  2010-04-24       Impact factor: 3.303

6.  Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa.

Authors:  Gail V Matthews; Prince Manzini; Zonghui Hu; Paul Khabo; Patrick Maja; Gugu Matchaba; Phumele Sangweni; Julie Metcalf; Nicholaas Pool; Susan Orsega; Sean Emery
Journal:  AIDS       Date:  2011-09-10       Impact factor: 4.177

7.  Carriage of GB virus C/hepatitis G virus RNA is associated with a slower immunologic, virologic, and clinical progression of human immunodeficiency virus disease in coinfected persons.

Authors:  J J Lefrère; F Roudot-Thoraval; L Morand-Joubert; J C Petit; J Lerable; M Thauvin; M Mariotti
Journal:  J Infect Dis       Date:  1999-04       Impact factor: 5.226

8.  Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort.

Authors:  Nimzing Gwamzhi Ladep; Patricia Aladi Agaba; Oche Agbaji; Auwal Muazu; Placid Ugoagwu; Godwin Imade; Graham Cooke; Sheena McCormack; Simon David Taylor-Robinson; John Idoko; Phyllis Kanki
Journal:  World J Gastroenterol       Date:  2013-03-14       Impact factor: 5.742

9.  Persistent GB virus C infection and survival in HIV-infected men.

Authors:  Carolyn F Williams; Donna Klinzman; Traci E Yamashita; Jinhua Xiang; Philip M Polgreen; Charles Rinaldo; Chenglong Liu; John Phair; Joseph B Margolick; Dietmar Zdunek; Georg Hess; Jack T Stapleton
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

10.  GB Virus C (GBV-C) Infection in Hepatitis C Virus (HCV) Seropositive Women with or at Risk for HIV Infection.

Authors:  Jason T Blackard; Gang Ma; Jeffrey A Welge; Caroline C King; Lynn E Taylor; Kenneth H Mayer; Robert S Klein; David D Celentano; Jack D Sobel; Denise J Jamieson; Lytt Gardner
Journal:  PLoS One       Date:  2014-12-10       Impact factor: 3.240

View more
  6 in total

1.  Semi-quantitative duplex RT-PCR reveals the low occurrence of Porcine Pegivirus and Atypical Porcine Pestivirus in diagnostic samples from the United States.

Authors:  Fangzhou Chen; Todd P Knutson; Eli Braun; Yin Jiang; Stephanie Rossow; Douglas G Marthaler
Journal:  Transbound Emerg Dis       Date:  2019-03-21       Impact factor: 5.005

2.  Role of human Pegivirus infections in whole Plasmodium falciparum sporozoite vaccination and controlled human malaria infection in African volunteers.

Authors:  Anneth-Mwasi Tumbo; Tobias Schindler; Jean-Pierre Dangy; Nina Orlova-Fink; Jose Raso Bieri; Maximillian Mpina; Florence A Milando; Omar Juma; Ali Hamad; Elizabeth Nyakarungu; Mwajuma Chemba; Ali Mtoro; Kamaka Ramadhan; Ally Olotu; Damas Makweba; Stephen Mgaya; Kenneth Stuart; Matthieu Perreau; Jack T Stapleton; Said Jongo; Stephen L Hoffman; Marcel Tanner; Salim Abdulla; Claudia Daubenberger
Journal:  Virol J       Date:  2021-01-26       Impact factor: 4.099

Review 3.  Human pegivirus infection after transplant: Is there an impact?

Authors:  Anna Mrzljak; Bojana Simunov; Ivan Balen; Zeljka Jurekovic; Tatjana Vilibic-Cavlek
Journal:  World J Transplant       Date:  2022-01-18

Review 4.  Review of human pegivirus: Prevalence, transmission, pathogenesis, and clinical implication.

Authors:  Yaqi Yu; Zhenzhou Wan; Jian-Hua Wang; Xianguang Yang; Chiyu Zhang
Journal:  Virulence       Date:  2022-12       Impact factor: 5.882

Review 5.  Clinical and molecular aspects of human pegiviruses in the interaction host and infectious agent.

Authors:  Mehdi Samadi; Vahid Salimi; Mohammad Reza Haghshenas; Seyed Mohammad Miri; Seyed Reza Mohebbi; Amir Ghaemi
Journal:  Virol J       Date:  2022-03-09       Impact factor: 4.099

6.  Clinical relevance of plasma virome dynamics in liver transplant recipients.

Authors:  Marijn Thijssen; Frank Tacke; Leen Beller; Ward Deboutte; Kwe Claude Yinda; Frederik Nevens; Wim Laleman; Marc Van Ranst; Mahmoud Reza Pourkarim
Journal:  EBioMedicine       Date:  2020-09-24       Impact factor: 8.143

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.